(Q45714550)

15 December 2017

title

Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer (English)

1 reference

15 December 2017

D H Boggs

1

1 reference

15 December 2017

C Tarabolous

2

1 reference

15 December 2017

C G Morris

3

1 reference

15 December 2017

A Hanna

4

1 reference

15 December 2017

W Burrows

5

1 reference

15 December 2017

N Horiba

6

1 reference

15 December 2017

M Suntharalingam

7

1 reference

15 December 2017

publication date

26 May 2014

1 reference

Diseases of the Esophagus

15 December 2017

published in

1 reference

15 December 2017

volume

28

1 reference

15 December 2017

issue

7

1 reference

15 December 2017

page(s)

619-625

1 reference

15 December 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Chemoradiation for esophageal cancer: institutional experience with three different regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

Population-based esophageal cancer survival after resection without neoadjuvant therapy: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDOTE.12243

21 January 2018

Identifiers

DOI

10.1111/DOTE.12243

1 reference

15 December 2017

1 reference